- Home
- NGEN vs HURA Comparison
NGEN vs HURA Comparison
Compare NGEN & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NGEN | HURA |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | Canada | United States |
| Employees | 9 | 22 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.1M | 144.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NGEN | HURA |
|---|---|---|
| Price | $2.07 | $2.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $18.00 | $9.50 |
| AVG Volume (30 Days) | ★ 1.0M | 557.8K |
| Earning Date | 04-02-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $0.41 |
| 52 Week High | $5.93 | $3.90 |
Technical Indicators
Market Signals| Indicator | NGEN | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 22.50 | 45.98 |
| Support Level | N/A | $2.24 |
| Resistance Level | $4.52 | $2.68 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | -0.18 | -0.03 |
| Stochastic Oscillator | 4.36 | 6.90 |
Price Performance
Historical ComparisonAbout NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.